High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: A case-control study

BMJ Open Diabetes Research and Care

Volumn 5, Issue 1, 2017, Pages

  Anoop, Shajith ^a,b   Misra, Anoop ^a,b,c,d   Bhatt, Surya Prakash ^a,b   Gulati, Seema ^a,b   Pandey, Ravindra Mohan ^e   Mahajan, Harsh ^f  

^a Obesity and Cholesterol Diseases Foundation N DOC   (India)

^b Diabetes Foundation India New Delhi   (India)

^c Metabolic Diseases and Endocrinology   (India)

^d FORTIS HOSPITAL   (India)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^f Mahajan Imaging Centre   (India)

Author keywords

abdominal obesity; Asian Indians; dp iv; mri

Indexed keywords

EID: 85041480368     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2017-000393     Document Type: Article

References (39)

1. Misra A, Khurana L. Obesity-related non-communicable diseases: South Asians vs White Caucasians. Int J Obes 2011;35:167-87.
2. Misra A, Anoop S, Gulati S, et al. Body fat patterning, hepatic fat and pancreatic volume of non-obese Asian Indians with type 2 diabetes in North India: a case-control study. PLoS One 2015;10:e0140447.
3. Mentzel S, Dijkman HB, Van Son JP, et al. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem 1996;44:445-61.
4. Rohrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol 2015;27:6-386.
5. Deacon CF, Knudsen LB, Madsen K, et al. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998;41:271-8.
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705.
7. Stengel A, Goebel-Stengel M, Teuffel P, et al. Obese patients have higher circulating protein levels of dipeptidyl peptidase IV. Peptides 2014;61:75-82.
8. Williams KH, Vieira De Ribeiro AJ, Prakoso E, et al. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: a dual cohort cross-sectional study. J Diabetes 2015;7:809-19.
9. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013;226:305-14.
10. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60:1917-25.
11. Ryskjaer J, Deacon CF, Carr RD, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006;155:485-93.
12. McKillop AM, Duffy NA, Lindsay JR, et al. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008;79:79-85.
13. Sell H, Bluher M, Kloting N, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 2013;36:4083-90.
14. Tahara N, Yamagishi S, Takeuchi M, et al. Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clin Biochem 2013;46:300-3.
15. Son JW, Kim S. Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies. Diabetes Metab J 2015;39:373-83.
16. Misra A, Garg A, Abate N, et al. Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. Obes Res 1997;5:93-9.
17. Marinou K, Hodson L, Vasan SK, et al. Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care 2014;37:821-9.
18. Anand SS, Tarnopolsky MA, Rashid S, et al. Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the molecular study of health and risk in ethnic groups (mol-SHARE). PLoS One 2011;6:e22112.
19. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-4.
20. Dudeja V, Misra A, Pandey RM, et al. BMI does not accurately predict overweight in Asian Indians in northern India. Br J Nutr 2001;86:105-12.
21. Goda K, Sasaki E, Nagata K, et al. Pancreatic volume in type 1 and type 2 diabetes mellitus. Acta Diabetol 2001;38:145-9.
22. Tanaka S, Kanazawa I, Notsu M, et al. Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus. Diabetes Res Clin Pract 2016;116:1-6.
23. Chandalia M, Lin P, Seenivasan T, et al. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. PLoS One 2007;2:e812.
24. Abate N, Garg A, Peshock RM, et al. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995;96:88-98.
25. Balaban YH, Korkusuz P, Simsek H, et al. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007;6:242-50.
26. Miyazaki M, Kato M, Tanaka K, et al. Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep 2012;5:729-33.
27. Petersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci U S A 2006;103:18273-7.
28. Lee SA, Kim YR, Yang EJ, et al. CD26/DPP4 levels in peripheral blood and T Cells in patients with Type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism 2013;98:2553-61.
29. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004;324:92-7.
30. Green BD, Irwin N, Duffy NA, et al. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. Eur J Pharmacol 2006;547:192-9.
31. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48:1168-72.
32. Pala L, Mannucci E, Pezzatini A, et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 2003;310:28-31.
33. Wu L, Gong Q, Na R, et al. Dipeptidyl peptidase 4 concentration influenced by serum insulin levels rather than arterial stiffness index in type 2 diabetics. Int J Clin Exp Med 2015;8:6236-41.
34. Firneisz G, Varga T, Lengyel G, et al. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 2010;5:e12226.
35. Zhong J, Rao X, Deiuliis J, et al. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes 2013;62:149-57.
36. Aso Y, Terasawa T, Kato K, et al. The serum level of soluble CD26/ dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Transl Res 2013;162:309-16.
37. Chandalia M, Cabo-Chan AV, Devaraj S, et al. Elevated plasma highsensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab 2003;88:3773-6.
38. Shrivastava U, Misra A, Mohan V, et al. Obesity, diabetes and cardiovascular diseases in India: public health challenges. Curr Diabetes Rev 2017;13:65-80.
39. Gupta R, Misra A. Epidemiology of microvascular complications of diabetes in South Asians and comparison with other ethnicities. J Diabetes 2016;8:470-82.